Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for ...